View Financial HealthSolara Active Pharma Sciences 配当と自社株買い配当金 基準チェック /06Solara Active Pharma Sciences現在配当金を支払っていません。主要情報0%配当利回り-5.9%バイバック利回り総株主利回り-5.9%将来の配当利回り0%配当成長n/a次回配当支払日n/a配当落ち日n/a一株当たり配当金n/a配当性向0%最近の配当と自社株買いの更新更新なしすべての更新を表示Recent updatesReported Earnings • May 18Full year 2026 earnings released: ₹1.68 loss per share (vs ₹0.14 profit in FY 2025)Full year 2026 results: ₹1.68 loss per share (down from ₹0.14 profit in FY 2025). Revenue: ₹13.8b (up 7.1% from FY 2025). Net loss: ₹74.1m (down ₹79.5m from profit in FY 2025). Over the last 3 years on average, earnings per share has increased by 32% per year but the company’s share price has only increased by 17% per year, which means it is significantly lagging earnings growth.New Risk • May 15New major risk - Revenue and earnings growthEarnings have declined by 44% per year over the past 5 years. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are declining over an extended period, then in most cases the share price will decline over time unless the company can turn around its fortunes. A trend of falling earnings can be very difficult to turn around. If the company is well already established it may also be a sign the company has matured and is in decline. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. This is currently the only risk that has been identified for the company.お知らせ • May 08Solara Active Pharma Sciences Limited to Report Q4, 2026 Results on May 15, 2026Solara Active Pharma Sciences Limited announced that they will report Q4, 2026 results on May 15, 2026Buy Or Sell Opportunity • Mar 27Now 22% undervalued after recent price dropOver the last 90 days, the stock has fallen 21% to ₹443. The fair value is estimated to be ₹567, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has declined by 6.9% over the last 3 years. Earnings per share has grown by 6.5%.Buy Or Sell Opportunity • Mar 09Now 21% undervalued after recent price dropOver the last 90 days, the stock has fallen 26% to ₹450. The fair value is estimated to be ₹566, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has declined by 6.9% over the last 3 years. Earnings per share has grown by 6.5%.Reported Earnings • Feb 07Third quarter 2026 earnings released: ₹3.98 loss per share (vs ₹2.03 profit in 3Q 2025)Third quarter 2026 results: ₹3.98 loss per share (down from ₹2.03 profit in 3Q 2025). Revenue: ₹3.49b (up 16% from 3Q 2025). Net loss: ₹174.3m (down 316% from profit in 3Q 2025). Revenue is forecast to grow 22% p.a. on average during the next 2 years, compared to a 10% growth forecast for the Pharmaceuticals industry in India. Over the last 3 years on average, earnings per share has increased by 7% per year and the company’s share price has also increased by 7% per year.お知らせ • Jan 30Solara Active Pharma Sciences Limited to Report Q3, 2026 Results on Feb 06, 2026Solara Active Pharma Sciences Limited announced that they will report Q3, 2026 results at 9:08 AM, Indian Standard Time on Feb 06, 2026Buy Or Sell Opportunity • Jan 05Now 20% undervalued after recent price dropOver the last 90 days, the stock has fallen 3.8% to ₹576. The fair value is estimated to be ₹722, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has declined by 3.9% over the last 3 years. Meanwhile, the company has become profitable. Revenue is forecast to grow by 44% in a year. Earnings are forecast to grow by 2,318% in the next year.Buy Or Sell Opportunity • Dec 18Now 21% undervalued after recent price dropOver the last 90 days, the stock has fallen 15% to ₹573. The fair value is estimated to be ₹722, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has declined by 3.9% over the last 3 years. Meanwhile, the company has become profitable. Revenue is forecast to grow by 44% in a year. Earnings are forecast to grow by 2,318% in the next year.分析記事 • Dec 10Calculating The Intrinsic Value Of Solara Active Pharma Sciences Limited (NSE:SOLARA)Key Insights Using the 2 Stage Free Cash Flow to Equity, Solara Active Pharma Sciences fair value estimate is ₹722...分析記事 • Nov 11Market Cool On Solara Active Pharma Sciences Limited's (NSE:SOLARA) RevenuesIt's not a stretch to say that Solara Active Pharma Sciences Limited's ( NSE:SOLARA ) price-to-sales (or "P/S") ratio...Buy Or Sell Opportunity • Nov 06Now 22% undervalued after recent price dropOver the last 90 days, the stock has fallen 4.3% to ₹563. The fair value is estimated to be ₹722, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has declined by 3.9% over the last 3 years. Meanwhile, the company has become profitable. Revenue is forecast to grow by 44% in a year. Earnings are forecast to grow by 2,318% in the next year.お知らせ • Oct 29Solara Active Pharma Sciences Limited to Report Q2, 2026 Results on Nov 05, 2025Solara Active Pharma Sciences Limited announced that they will report Q2, 2026 results on Nov 05, 2025お知らせ • Sep 02Solara Active Pharma Sciences Limited, Annual General Meeting, Sep 25, 2025Solara Active Pharma Sciences Limited, Annual General Meeting, Sep 25, 2025, at 10:30 Indian Standard Time.Reported Earnings • Jul 26First quarter 2026 earnings released: EPS: ₹2.46 (vs ₹3.50 loss in 1Q 2025)First quarter 2026 results: EPS: ₹2.46 (up from ₹3.50 loss in 1Q 2025). Revenue: ₹3.19b (down 12% from 1Q 2025). Net income: ₹105.2m (up ₹239.8m from 1Q 2025). Profit margin: 3.3% (up from net loss in 1Q 2025). The move to profitability was driven by lower expenses. Revenue is forecast to grow 19% p.a. on average during the next 2 years, compared to a 10% growth forecast for the Pharmaceuticals industry in India. Over the last 3 years on average, earnings per share has fallen by 26% per year but the company’s share price has increased by 22% per year, which means it is well ahead of earnings.分析記事 • Jul 19Further Upside For Solara Active Pharma Sciences Limited (NSE:SOLARA) Shares Could Introduce Price Risks After 29% BounceSolara Active Pharma Sciences Limited ( NSE:SOLARA ) shareholders have had their patience rewarded with a 29% share...お知らせ • Jul 18Solara Active Pharma Sciences Limited to Report Q1, 2026 Results on Jul 25, 2025Solara Active Pharma Sciences Limited announced that they will report Q1, 2026 results on Jul 25, 2025分析記事 • Jun 26These 4 Measures Indicate That Solara Active Pharma Sciences (NSE:SOLARA) Is Using Debt Reasonably WellThe external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...New Risk • Jun 25New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Indian stocks, typically moving 7.7% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Interest payments are not well covered by earnings (0.9x net interest cover). Minor Risk Share price has been volatile over the past 3 months (7.7% average weekly change).Board Change • May 21High number of new directorsThere are 5 new directors who have joined the board in the last 3 years. CEO & MD Sandeep Rao was the last director to join the board, commencing their role in 2025. The company’s lack of board continuity is considered a risk according to the Simply Wall St Risk Model.お知らせ • May 10Solara Active Pharma Sciences Limited to Report Q4, 2025 Results on May 15, 2025Solara Active Pharma Sciences Limited announced that they will report Q4, 2025 results on May 15, 2025お知らせ • Feb 23Solara Active Pharma Sciences Limited Announces Resignation of Poorvank Purohit as CEOSolara Active Pharma Sciences Limited at the Board of Directors meeting held on February 21, 2025 Mr. Poorvank Purohit tendered his resignation as the CEO of the Company, with effect from February 21, 2025, citing personal reasons.お知らせ • Feb 21+ 2 more updatesSolara Active Pharma Sciences Limited Approves Closure of Solara Active Pharma Sciences LTDA, BrazilSolara Active Pharma Sciences Limited at its board meeting held on February 21, 2025, transacted and approved the proposal for closure of Solara Active Pharma Sciences LTDA, Brazil, Wholly Owned Subsidiary of the Company as there were no operations.分析記事 • Jan 29Market Cool On Solara Active Pharma Sciences Limited's (NSE:SOLARA) Revenues Pushing Shares 25% LowerUnfortunately for some shareholders, the Solara Active Pharma Sciences Limited ( NSE:SOLARA ) share price has dived 25...Reported Earnings • Jan 25Third quarter 2025 earnings released: EPS: ₹2.03 (vs ₹76.34 loss in 3Q 2024)Third quarter 2025 results: EPS: ₹2.03 (up from ₹76.34 loss in 3Q 2024). Revenue: ₹3.02b (up 21% from 3Q 2024). Net income: ₹80.9m (up ₹2.83b from 3Q 2024). Profit margin: 2.7% (up from net loss in 3Q 2024). Revenue is forecast to grow 12% p.a. on average during the next 3 years, compared to a 11% growth forecast for the Pharmaceuticals industry in India. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 66 percentage points per year, which is a significant difference in performance.お知らせ • Jan 25Solara Active Pharma Sciences Limited Revises Earnings Guidance for the Year 2025Solara Active Pharma Sciences Limited revised earnings guidance for the year 2025. The company will not get to the INR 14,000 million - INR 15,000 million range. The company will be more in the INR 13,000 million - INR 14,000 million range, which means that there is a drop in approximately INR 1,000 million of revenue.お知らせ • Jan 16Solara Active Pharma Sciences Limited to Report Q3, 2025 Results on Jan 24, 2025Solara Active Pharma Sciences Limited announced that they will report Q3, 2025 results on Jan 24, 2025New Risk • Jan 16New major risk - Shareholder dilutionThe company's shareholders have been substantially diluted in the past year. Increase in shares outstanding: 33% This is considered a major risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. This is currently the only risk that has been identified for the company.Reported Earnings • Oct 24Second quarter 2025 earnings released: EPS: ₹2.54 (vs ₹4.77 loss in 2Q 2024)Second quarter 2025 results: EPS: ₹2.54 (up from ₹4.77 loss in 2Q 2024). Revenue: ₹3.47b (down 18% from 2Q 2024). Net income: ₹80.1m (up ₹251.7m from 2Q 2024). Profit margin: 2.3% (up from net loss in 2Q 2024). Revenue is forecast to grow 13% p.a. on average during the next 3 years, compared to a 11% growth forecast for the Pharmaceuticals industry in India. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 86 percentage points per year, which is a significant difference in performance.お知らせ • Oct 14Solara Active Pharma Sciences Limited to Report Q2, 2025 Results on Oct 21, 2024Solara Active Pharma Sciences Limited announced that they will report Q2, 2025 results on Oct 21, 2024Recent Insider Transactions • Sep 29Independent Chairman recently bought ₹2.4m worth of stockOn the 26th of September, Ramakrishnan Rajagopal bought around 3k shares on-market at roughly ₹808 per share. This transaction increased Ramakrishnan's direct individual holding by 2x at the time of the trade. This was the largest purchase by an insider in the last 3 months. This was Ramakrishnan's only on-market trade for the last 12 months.分析記事 • Sep 13The Market Lifts Solara Active Pharma Sciences Limited (NSE:SOLARA) Shares 26% But It Can Do MoreSolara Active Pharma Sciences Limited ( NSE:SOLARA ) shares have continued their recent momentum with a 26% gain in the...お知らせ • Aug 28Solara Active Pharma Sciences Limited, Annual General Meeting, Sep 20, 2024Solara Active Pharma Sciences Limited, Annual General Meeting, Sep 20, 2024, at 10:00 Indian Standard Time.Price Target Changed • Jul 23Price target increased by 40% to ₹485Up from ₹347, the current price target is provided by 1 analyst. New target price is 20% below last closing price of ₹604. Stock is up 54% over the past year. The company is forecast to post earnings per share of ₹8.30 next year compared to a net loss per share of ₹158 last year.Reported Earnings • Jul 23First quarter 2025 earnings released: ₹3.50 loss per share (vs ₹5.43 loss in 1Q 2024)First quarter 2025 results: ₹3.50 loss per share (improved from ₹5.43 loss in 1Q 2024). Revenue: ₹3.63b (up 3.2% from 1Q 2024). Net loss: ₹134.6m (loss narrowed 31% from 1Q 2024). Revenue is forecast to grow 13% p.a. on average during the next 3 years, compared to a 9.9% growth forecast for the Pharmaceuticals industry in India. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 86 percentage points per year, which is a significant difference in performance.分析記事 • Jul 20Further Upside For Solara Active Pharma Sciences Limited (NSE:SOLARA) Shares Could Introduce Price Risks After 30% BounceSolara Active Pharma Sciences Limited ( NSE:SOLARA ) shareholders are no doubt pleased to see that the share price has...お知らせ • Jul 16Solara Active Pharma Sciences Limited to Report Q1, 2025 Results on Jul 22, 2024Solara Active Pharma Sciences Limited announced that they will report Q1, 2025 results on Jul 22, 2024Price Target Changed • Jun 20Price target increased by 9.7% to ₹381Up from ₹347, the current price target is an average from 2 analysts. New target price is 15% below last closing price of ₹448. Stock is up 22% over the past year. The company is forecast to post earnings per share of ₹8.70 next year compared to a net loss per share of ₹158 last year.Buy Or Sell Opportunity • Jun 06Now 25% overvaluedOver the last 90 days, the stock has fallen 1.0% to ₹425. The fair value is estimated to be ₹339, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has declined by 3.4% over the last 3 years. Meanwhile, the company became loss making. Revenue is forecast to grow by 12% in a year. Earnings are forecast to grow by 84% in the next year.分析記事 • Jun 05Slammed 32% Solara Active Pharma Sciences Limited (NSE:SOLARA) Screens Well Here But There Might Be A CatchSolara Active Pharma Sciences Limited ( NSE:SOLARA ) shareholders won't be pleased to see that the share price has had...New Risk • May 24New minor risk - Shareholder dilutionThe company's shareholders have been diluted in the past year. Increase in shares outstanding: 33% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Debt is not well covered by operating cash flow (15% operating cash flow to total debt). Share price has been highly volatile over the past 3 months (10.0% average weekly change). Minor Risk Shareholders have been diluted in the past year (33% increase in shares outstanding).お知らせ • May 23Solara Active Pharma Sciences Limited to Report Q4, 2024 Results on May 29, 2024Solara Active Pharma Sciences Limited announced that they will report Q4, 2024 results on May 29, 2024分析記事 • May 11A Look At The Fair Value Of Solara Active Pharma Sciences Limited (NSE:SOLARA)Key Insights Solara Active Pharma Sciences' estimated fair value is ₹457 based on 2 Stage Free Cash Flow to Equity...Buy Or Sell Opportunity • May 03Now 21% overvalued after recent price riseOver the last 90 days, the stock has risen 38% to ₹554. The fair value is estimated to be ₹458, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has declined by 3.4% over the last 3 years. Meanwhile, the company became loss making. Revenue is forecast to grow by 16% in a year. Earnings are forecast to grow by 81% in the next year.Buy Or Sell Opportunity • Apr 19Now 20% overvalued after recent price riseOver the last 90 days, the stock has risen 35% to ₹552. The fair value is estimated to be ₹458, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has declined by 3.4% over the last 3 years. Meanwhile, the company became loss making. Revenue is forecast to grow by 16% in a year. Earnings are forecast to grow by 81% in the next year.分析記事 • Apr 19Investors Still Aren't Entirely Convinced By Solara Active Pharma Sciences Limited's (NSE:SOLARA) Revenues Despite 28% Price JumpSolara Active Pharma Sciences Limited ( NSE:SOLARA ) shareholders would be excited to see that the share price has had...Price Target Changed • Apr 04Price target decreased by 15% to ₹350Down from ₹410, the current price target is an average from 2 analysts. New target price is 15% below last closing price of ₹412. Stock is up 22% over the past year. The company posted a net loss per share of ₹6.16 last year.お知らせ • Mar 25An undisclosed buyer agreed to acquire SeQuent Penems Private Limited from Solara Active Pharma Sciences Limited (NSEI:SOLARA).An undisclosed buyer agreed to acquire SeQuent Penems Private Limited from Solara Active Pharma Sciences Limited (NSEI:SOLARA) on March 25, 2024.分析記事 • Mar 13Is Solara Active Pharma Sciences (NSE:SOLARA) A Risky Investment?Warren Buffett famously said, 'Volatility is far from synonymous with risk.' It's only natural to consider a company's...分析記事 • Feb 23Even With A 26% Surge, Cautious Investors Are Not Rewarding Solara Active Pharma Sciences Limited's (NSE:SOLARA) Performance CompletelyDespite an already strong run, Solara Active Pharma Sciences Limited ( NSE:SOLARA ) shares have been powering on, with...Reported Earnings • Feb 16Third quarter 2024 earnings released: ₹76.49 loss per share (vs ₹0.12 profit in 3Q 2023)Third quarter 2024 results: ₹76.49 loss per share (down from ₹0.12 profit in 3Q 2023). Revenue: ₹2.49b (down 37% from 3Q 2023). Net loss: ₹2.75b (down ₹2.76b from profit in 3Q 2023). Revenue is forecast to grow 11% p.a. on average during the next 3 years, compared to a 11% growth forecast for the Pharmaceuticals industry in India. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 76 percentage points per year, which is a significant difference in performance.お知らせ • Feb 14Solara Active Pharma Sciences Limited Announces the Resignation of P.V. Raghavendra Rao as Chief Financial OfficerSolara Active Pharma Sciences Limited at its meeting held on February 14, 2024 announced that Mr. P.V. Raghavendra Rao resigned as Chief Financial Officer of the Company from the close of business hours on February 15, 2024, due to personal reasons.お知らせ • Feb 06Solara Active Pharma Sciences Limited to Report Q3, 2024 Results on Feb 14, 2024Solara Active Pharma Sciences Limited announced that they will report Q3, 2024 results on Feb 14, 2024分析記事 • Jan 04Further Upside For Solara Active Pharma Sciences Limited (NSE:SOLARA) Shares Could Introduce Price Risks After 25% BounceSolara Active Pharma Sciences Limited ( NSE:SOLARA ) shareholders would be excited to see that the share price has had...Board Change • Dec 01High number of new directorsThere are 5 new directors who have joined the board in the last 3 years. Independent Director Rajendra Srivastava was the last director to join the board, commencing their role in 2023. The company’s lack of board continuity is considered a risk according to the Simply Wall St Risk Model.Reported Earnings • Nov 16Second quarter 2024 earnings released: ₹4.77 loss per share (vs ₹2.77 loss in 2Q 2023)Second quarter 2024 results: ₹4.77 loss per share (further deteriorated from ₹2.77 loss in 2Q 2023). Revenue: ₹4.26b (up 26% from 2Q 2023). Net loss: ₹171.6m (loss widened 72% from 2Q 2023). Revenue is forecast to grow 13% p.a. on average during the next 2 years, compared to a 10% growth forecast for the Pharmaceuticals industry in India. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 67 percentage points per year, which is a significant difference in performance.お知らせ • Oct 20Solara Active Pharma Sciences Limited Appoints P V Raghavendra Rao as Chief Financial OfficerSolara Active Pharma Sciences Limited at its board meeting held on October 19, 2023, approved the appointment of Mr. P V Raghavendra Rao as Chief Financial Officer (CFO) of the Company and designated him as Key Managerial Personnel with effect from October 26, 2023. Mr. P V Raghavendra Rao is a Chartered Accountant from the Institute of Chartered Accountants of India and has close to 23 years of post-qualification work experience. Mr. Rao has a strong track record of handling multiple industries including pharmaceuticals. He comes from Sequent Scientific Limited, where he was the Chief Financial Officer. Before this, he was at Macleods Pharmaceuticals Ltd. and Dr. Reddy's Laboratories Limited, for over 14 years where he handled various roles in finance such as Finance Head Pharmaceutical Services and Active Ingredients, Finance Head FTOs (Formulation Technical Operations), Finance Head Rest of World Markets and Finance Head Integrated Product Development Organization. Prior to Dr. Reddy's he was at New Holland Tractors. Mr. Rao started his career at Indo Asian Fusegear Limited, India, where he worked for 2 years.Price Target Changed • Oct 11Price target decreased by 9.0% to ₹407Down from ₹447, the current price target is an average from 3 analysts. New target price is 20% above last closing price of ₹338. Stock is down 19% over the past year. The company is forecast to post earnings per share of ₹18.00 next year compared to a net loss per share of ₹6.16 last year.Recent Insider Transactions • Sep 04Independent Director recently sold ₹183k worth of stockOn the 28th of August, Ramakrishnan Rajagopal sold around 500 shares on-market at roughly ₹366 per share. This transaction amounted to 100% of their direct individual holding at the time of the trade. In the last 3 months, they made an even bigger sale worth ₹7.3m. Insiders have been net sellers, collectively disposing of ₹25m more than they bought in the last 12 months.お知らせ • Aug 22Solara Active Pharma Sciences Limited, Annual General Meeting, Sep 15, 2023Solara Active Pharma Sciences Limited, Annual General Meeting, Sep 15, 2023, at 09:30 Indian Standard Time. Agenda: To consider the Audited Standalone Financial Statements of the Company for the Financial Year ended March 31, 2023, together with the Reports of Board of Directors and Auditors thereon; to consider the Audited Consolidated Financial Statements of the Company for the Financial Year ended March 31, 2023, and the Report of Auditors thereon; to consider Board changes; and to consider any other matter thereof.Buying Opportunity • Aug 17Now 20% undervalued after recent price dropOver the last 90 days, the stock is down 1.0%. The fair value is estimated to be ₹457, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has declined by 3.1% over the last 3 years. Meanwhile, the company became loss making.Reported Earnings • Aug 16First quarter 2024 earnings released: ₹5.43 loss per share (vs ₹4.56 loss in 1Q 2023)First quarter 2024 results: ₹5.43 loss per share (further deteriorated from ₹4.56 loss in 1Q 2023). Revenue: ₹3.52b (up 6.7% from 1Q 2023). Net loss: ₹195.5m (loss widened 19% from 1Q 2023). Revenue is forecast to grow 13% p.a. on average during the next 2 years, compared to a 9.9% growth forecast for the Pharmaceuticals industry in India. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 67 percentage points per year, which is a significant difference in performance.お知らせ • Aug 05+ 1 more updateSolara Active Pharma Sciences Limited Announces Resignation of DirectorsSolara Active Pharma Sciences Limited informed that following directors have resigned from the directorship of the company with effect from August 5, 2023, Mr. Aditya Puri (DIN: 00062650) has resigned from the position of Chairman and Non- Executive Director of the Company due to personal reasons. Mrs. Vineeta Rai (DIN: 07013113) has resigned from the position of Non- Executive- Independent Director of the Company due to personal reasons.Names of listed entities in which Mrs. Vineeta Rai (DIN: 07013113) holds directorships, indicating the category of directorship and membership of board committees:- Indraprastha Medical Corporation Limited as Independent Director. Membership of Board Committees: Audit Committee Member and Nomination and remuneration Committee Member.Board Change • Aug 04High number of new directorsThere are 5 new directors who have joined the board in the last 3 years. MD, CEO & Director Poorvank Purohit was the last director to join the board, commencing their role in 2023. The company’s lack of board continuity is considered a risk according to the Simply Wall St Risk Model.お知らせ • Aug 03Solara Active Pharma Sciences Limited Announces Executive ChangesSolara Active Pharma Sciences Limited announced that Mr. Rajeev Singh has tendered his resignation from the position of Chief Human Resource Officer (CHRO) for better future prospects, the resignation letter is enclosed herewith as Annexure A. As a result, he will cease to be Head of Human Resources (CHRO) with effect from the close of business hours on August 31, 2023. Mr. Pagadala Srinivasan has been appointed as Chief Human Resource Officer(CHRO) with effect from August 1, 2023. He has over 23 years' experience working across reputed pharma companies in India. He joins from Biological E. Ltd. His experience is in handling all gamut of HR.お知らせ • Aug 01+ 1 more updateSolara Active Pharma Sciences Limited Announces Resignation of S Hariharan as Executive DirectorSolara Active Pharma Sciences Limited announced that Mr. S Hariharan (DIN: 05297969) has resigned from the position of Executive Director of the Company from the close of business hours on July 31, 2023, due to personal reasons. The Company will announce his successor in due course. Date of cessation:The resignation is effective from the close of business hours on July 31, 2023.お知らせ • Jul 06Solara Active Pharma Sciences Limited Announces Resignation of Jitesh Devendra as A Managing Director and DirectorSolara Active Pharma Sciences Limited announced the resignation of Mr. Jitesh Devendra (DIN: 06469234) as a Managing Director (MD) and Director and KMP of the company due to pre-occupation. In view of resignation of Mr. Jitesh Devendra (DIN: 06469234) as Managing Director w.e.f. July 5, 2023, the Board of Directors of the Company have also approved the reconstitution of Risk Management Committee and Corporate Social Responsibility Committee.Recent Insider Transactions • Jun 29MD & Director recently sold ₹5.5m worth of stockOn the 23rd of June, Jitesh Devendra sold around 15k shares on-market at roughly ₹369 per share. This transaction amounted to 4.8% of their direct individual holding at the time of the trade. In the last 3 months, there was an even bigger sale from another insider worth ₹7.3m. Insiders have been net sellers, collectively disposing of ₹22m more than they bought in the last 12 months.Recent Insider Transactions • Jun 13Independent Director recently sold ₹7.3m worth of stockOn the 7th of June, Ramakrishnan Rajagopal sold around 21k shares on-market at roughly ₹354 per share. This transaction amounted to 98% of their direct individual holding at the time of the trade. This was the largest sale by an insider in the last 3 months. Insiders have been net sellers, collectively disposing of ₹11m more than they bought in the last 12 months.Recent Insider Transactions • May 31Insider recently sold ₹3.6m worth of stockOn the 26th of May, Chaitanya Devendra sold around 10k shares on-market at roughly ₹359 per share. This transaction amounted to 19% of their direct individual holding at the time of the trade. This was the largest sale by an insider in the last 3 months. Insiders have been net sellers, collectively disposing of ₹3.3m more than they bought in the last 12 months.Recent Insider Transactions • May 21Insider recently sold ₹1.8m worth of stockOn the 17th of May, Sajjan Devendra sold around 5k shares on-market at roughly ₹369 per share. This transaction amounted to 33% of their direct individual holding at the time of the trade. This was the largest sale by an insider in the last 3 months. Despite this recent sale, insiders have collectively bought ₹306k more than they sold in the last 12 months.Price Target Changed • May 17Price target decreased by 8.9% to ₹447Down from ₹491, the current price target is an average from 4 analysts. New target price is 18% above last closing price of ₹378. Stock is down 16% over the past year. The company is forecast to post earnings per share of ₹16.97 next year compared to a net loss per share of ₹6.16 last year.Reported Earnings • May 13Full year 2023 earnings: EPS exceeds analyst expectations while revenues lag behindFull year 2023 results: ₹6.16 loss per share (improved from ₹16.18 loss in FY 2022). Revenue: ₹14.7b (up 16% from FY 2022). Net loss: ₹221.7m (loss narrowed 62% from FY 2022). Revenue missed analyst estimates by 1.7%. Earnings per share (EPS) exceeded analyst estimates by 33%. Revenue is forecast to grow 13% p.a. on average during the next 2 years, compared to a 11% growth forecast for the Pharmaceuticals industry in India. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 80 percentage points per year, which is a significant difference in performance.分析記事 • May 12Solara Active Pharma Sciences Limited's (NSE:SOLARA) Intrinsic Value Is Potentially 81% Above Its Share PriceKey Insights Using the 2 Stage Free Cash Flow to Equity, Solara Active Pharma Sciences fair value estimate is ₹747...お知らせ • May 05Solara Active Pharma Sciences Limited to Report Q4, 2023 Results on May 12, 2023Solara Active Pharma Sciences Limited announced that they will report Q4, 2023 results on May 12, 2023Price Target Changed • Apr 08Price target decreased by 8.1% to ₹491Down from ₹534, the current price target is an average from 3 analysts. New target price is 45% above last closing price of ₹339. Stock is down 57% over the past year. The company is forecast to post a net loss per share of ₹10.80 next year compared to a net loss per share of ₹16.18 last year.お知らせ • Jan 31USFDA concludes inspection at Solara's Visakhapatnam (Vizag) facility with Zero 483 inspectional observationsSolara Active Pharma Sciences Ltd. (Solara) announced that its new state-of-the-art multipurpose API manufacturing facility at Visakhapatnam (Vizag), Andhra Pradesh completed successfully the inspection carried out by the US Food and Drug Administration (US FDA or Agency). The Agency, with its designated investigator, inspected the facility from 23rd to 26th January 2023. The inspection established that the site is in an "Acceptable State of Compliance" with Zero Form 483 inspectional observations from the agency. The Vizag facility of the Company is a green field project spread over 40 acres and has dedicated facilities for manufacturing Ibuprofen API and multipurpose facility in phase 1. The facility has also started validating other APIs to register in various regulated markets across the globe. The site offers a unique capability to the Company for manufacturing various APIs with scale and operational flexibility to achieve a competitive advantage. The site positions Solara as the only Global Company offering Ibuprofen from two USFDA-approved manufacturing sites (Puducherry and Vizag), enhancing supplies for its global partners. Earlier, in November 2022, Solara's Vizag facility had received a Certificate of Suitability (CEP) approval for the manufacture of Ibuprofen API from the European Directorate for the Quality of Medicines (EDQM), the first international regulatory approval for this new facility.Reported Earnings • Jan 26Third quarter 2023 earnings released: EPS: ₹0.12 (vs ₹38.93 loss in 3Q 2022)Third quarter 2023 results: EPS: ₹0.12 (up from ₹38.93 loss in 3Q 2022). Revenue: ₹4.02b (up 301% from 3Q 2022). Net income: ₹4.50m (up ₹1.40b from 3Q 2022). Profit margin: 0.1% (up from net loss in 3Q 2022). The move to profitability was driven by higher revenue. Revenue is forecast to grow 12% p.a. on average during the next 3 years, compared to a 11% growth forecast for the Pharmaceuticals industry in India. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 76 percentage points per year, which is a significant difference in performance.お知らせ • Jan 26Solara Active Pharma Sciences Limited Appoints Poorvank Purohit as Chief Executive Officer, Effective from 3 February, 2023Solara Active Pharma Sciences Limited informed that the Board of Directors of the Company has taken on record/approved the following changes in the Key Managerial Personnel (KMP) at its meeting held on January 25, 2023. The board approved the appointment of Mr. Poorvank Purohit as the Chief Executive Officer. The position of CEO has been vacant since the exit of previous MD & CEO, Mr. Rajender Rao Juvvadi. This appointment is effective from 3rd February, 2023 Mr. Purohit hold a Bachelor in Chemical Engineering from M.S.Ramaiah Institute of Technology, Bangalore. He has also done Executive MBA from IIM Bangalore and completed Advance Management Program from Wharton School. He started his career as Management Trainee with Ranbaxy and progressed through various roles in leading pharma companies Hikel, Alembic, Jubliant Organosys - strong B2B experience in both APIs and Finished Dosage Forms. He is currently the Chief Operating Officer (COO) with R L Fine Chem Pvt Ltd, Bangalore. He has to his credit experience of turning round companies for exponential growth and sustainable organization. His achievement includes building B2B businesses across geographies by establishing strong network and relationship with top Innovator/Generic/Dossier companies including CDMO companies. Holds a strong technical, commercial and management background.お知らせ • Jan 20Solara Active Pharma Sciences Limited to Report Q3, 2023 Results on Jan 25, 2023Solara Active Pharma Sciences Limited announced that they will report Q3, 2023 results at 12:08 PM, Indian Standard Time on Jan 25, 2023Board Change • Nov 16High number of new directorsThere are 6 new directors who have joined the board in the last 3 years. Managing Director Jitesh Devendra was the last director to join the board, commencing their role in 2022. The company’s lack of board continuity is considered a risk according to the Simply Wall St Risk Model.Reported Earnings • Nov 11Second quarter 2023 earnings released: ₹2.77 loss per share (vs ₹8.27 profit in 2Q 2022)Second quarter 2023 results: ₹2.77 loss per share (down from ₹8.27 profit in 2Q 2022). Revenue: ₹3.38b (down 16% from 2Q 2022). Net loss: ₹99.6m (down 134% from profit in 2Q 2022). Revenue is forecast to grow 15% p.a. on average during the next 3 years, compared to a 11% growth forecast for the Pharmaceuticals industry in India. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 65 percentage points per year, which is a significant difference in performance.分析記事 • Nov 08Estimating The Intrinsic Value Of Solara Active Pharma Sciences Limited (NSE:SOLARA)Today we'll do a simple run through of a valuation method used to estimate the attractiveness of Solara Active Pharma...Buying Opportunity • Oct 31Now 21% undervaluedOver the last 90 days, the stock is up 1.3%. The fair value is estimated to be ₹501, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has been flat over the last 3 years. Meanwhile, the company became loss making. Revenue is forecast to grow by 26% in a year. Earnings is forecast to grow by 98% in the next year.Buying Opportunity • Oct 07Now 20% undervaluedOver the last 90 days, the stock is up 14%. The fair value is estimated to be ₹547, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has been flat over the last 3 years. Meanwhile, the company became loss making. Revenue is forecast to grow by 26% in a year. Earnings is forecast to grow by 98% in the next year.分析記事 • Sep 30Is Solara Active Pharma Sciences (NSE:SOLARA) A Risky Investment?David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...Buying Opportunity • Sep 16Now 20% undervaluedOver the last 90 days, the stock is up 22%. The fair value is estimated to be ₹537, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has been flat over the last 3 years. Meanwhile, the company became loss making. Revenue is forecast to grow by 26% in a year. Earnings is forecast to grow by 98% in the next year.Recent Insider Transactions • Sep 03Insider recently bought ₹390k worth of stockOn the 29th of August, Shankarlal Devendra bought around 900 shares on-market at roughly ₹433 per share. This transaction increased Shankarlal Devendra's direct individual holding by 9x at the time of the trade. In the last 3 months, there was an even bigger purchase from another insider worth ₹1.3m. Insiders have collectively bought ₹117m more in shares than they have sold in the last 12 months.Recent Insider Transactions • Aug 26Insider recently bought ₹1.3m worth of stockOn the 19th of August, Pooja Srisrimal bought around 3k shares on-market at roughly ₹435 per share. This was the largest purchase by an insider in the last 3 months. Insiders have collectively bought ₹124m more in shares than they have sold in the last 12 months.Buying Opportunity • Aug 19Now 20% undervaluedThe stock has been flat over the last 90 days. The fair value is estimated to be ₹544, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has been flat over the last 3 years. Meanwhile, the company became loss making. Revenue is forecast to grow by 26% in a year. Earnings is forecast to grow by 98% in the next year.Reported Earnings • Aug 03Full year 2022 earnings: EPS and revenues miss analyst expectationsFull year 2022 results: ₹16.18 loss per share (down from ₹69.00 profit in FY 2021). Revenue: ₹12.7b (down 22% from FY 2021). Net loss: ₹581.5m (down 126% from profit in FY 2021). Revenue missed analyst estimates by 15%. Earnings per share (EPS) were also behind analyst expectations. Over the next year, revenue is forecast to grow 25%, compared to a 13% growth forecast for the pharmaceuticals industry in India. Over the last 3 years on average, earnings per share has fallen by 49% per year but the company’s share price has increased by 1% per year, which means it is well ahead of earnings.分析記事 • Aug 03Are Investors Undervaluing Solara Active Pharma Sciences Limited (NSE:SOLARA) By 22%?Does the August share price for Solara Active Pharma Sciences Limited ( NSE:SOLARA ) reflect what it's really worth...分析記事 • Jun 19Solara Active Pharma Sciences (NSE:SOLARA) Is Making Moderate Use Of DebtThe external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...決済の安定と成長配当データの取得安定した配当: SOLARAの 1 株当たり配当が過去に安定していたかどうかを判断するにはデータが不十分です。増加する配当: SOLARAの配当金が増加しているかどうかを判断するにはデータが不十分です。配当利回り対市場Solara Active Pharma Sciences 配当利回り対市場SOLARA 配当利回りは市場と比べてどうか？セグメント配当利回り会社 (SOLARA)0%市場下位25% (IN)0.3%市場トップ25% (IN)1.5%業界平均 (Pharmaceuticals)0.7%アナリスト予想 (SOLARA) (最長3年)0%注目すべき配当: SOLARAは最近配当金を報告していないため、配当金支払者の下位 25% に対して同社の配当利回りを評価することはできません。高配当: SOLARAは最近配当金を報告していないため、配当金支払者の上位 25% に対して同社の配当利回りを評価することはできません。株主への利益配当収益カバレッジ: SOLARA Indian市場において目立った配当金を支払っていません。株主配当金キャッシュフローカバレッジ: SOLARAが配当金を報告していないため、配当金の持続可能性を計算できません。高配当企業の発掘7D1Y7D1Y7D1YIN 市場の強力な配当支払い企業。View Management企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/05/25 21:09終値2026/05/25 00:00収益2026/03/31年間収益2026/03/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレーク本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋Solara Active Pharma Sciences Limited 0 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。2 アナリスト機関null nullAntique Stockbroking Ltd.Alankar GarudeMacquarie Research
Reported Earnings • May 18Full year 2026 earnings released: ₹1.68 loss per share (vs ₹0.14 profit in FY 2025)Full year 2026 results: ₹1.68 loss per share (down from ₹0.14 profit in FY 2025). Revenue: ₹13.8b (up 7.1% from FY 2025). Net loss: ₹74.1m (down ₹79.5m from profit in FY 2025). Over the last 3 years on average, earnings per share has increased by 32% per year but the company’s share price has only increased by 17% per year, which means it is significantly lagging earnings growth.
New Risk • May 15New major risk - Revenue and earnings growthEarnings have declined by 44% per year over the past 5 years. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are declining over an extended period, then in most cases the share price will decline over time unless the company can turn around its fortunes. A trend of falling earnings can be very difficult to turn around. If the company is well already established it may also be a sign the company has matured and is in decline. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. This is currently the only risk that has been identified for the company.
お知らせ • May 08Solara Active Pharma Sciences Limited to Report Q4, 2026 Results on May 15, 2026Solara Active Pharma Sciences Limited announced that they will report Q4, 2026 results on May 15, 2026
Buy Or Sell Opportunity • Mar 27Now 22% undervalued after recent price dropOver the last 90 days, the stock has fallen 21% to ₹443. The fair value is estimated to be ₹567, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has declined by 6.9% over the last 3 years. Earnings per share has grown by 6.5%.
Buy Or Sell Opportunity • Mar 09Now 21% undervalued after recent price dropOver the last 90 days, the stock has fallen 26% to ₹450. The fair value is estimated to be ₹566, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has declined by 6.9% over the last 3 years. Earnings per share has grown by 6.5%.
Reported Earnings • Feb 07Third quarter 2026 earnings released: ₹3.98 loss per share (vs ₹2.03 profit in 3Q 2025)Third quarter 2026 results: ₹3.98 loss per share (down from ₹2.03 profit in 3Q 2025). Revenue: ₹3.49b (up 16% from 3Q 2025). Net loss: ₹174.3m (down 316% from profit in 3Q 2025). Revenue is forecast to grow 22% p.a. on average during the next 2 years, compared to a 10% growth forecast for the Pharmaceuticals industry in India. Over the last 3 years on average, earnings per share has increased by 7% per year and the company’s share price has also increased by 7% per year.
お知らせ • Jan 30Solara Active Pharma Sciences Limited to Report Q3, 2026 Results on Feb 06, 2026Solara Active Pharma Sciences Limited announced that they will report Q3, 2026 results at 9:08 AM, Indian Standard Time on Feb 06, 2026
Buy Or Sell Opportunity • Jan 05Now 20% undervalued after recent price dropOver the last 90 days, the stock has fallen 3.8% to ₹576. The fair value is estimated to be ₹722, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has declined by 3.9% over the last 3 years. Meanwhile, the company has become profitable. Revenue is forecast to grow by 44% in a year. Earnings are forecast to grow by 2,318% in the next year.
Buy Or Sell Opportunity • Dec 18Now 21% undervalued after recent price dropOver the last 90 days, the stock has fallen 15% to ₹573. The fair value is estimated to be ₹722, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has declined by 3.9% over the last 3 years. Meanwhile, the company has become profitable. Revenue is forecast to grow by 44% in a year. Earnings are forecast to grow by 2,318% in the next year.
分析記事 • Dec 10Calculating The Intrinsic Value Of Solara Active Pharma Sciences Limited (NSE:SOLARA)Key Insights Using the 2 Stage Free Cash Flow to Equity, Solara Active Pharma Sciences fair value estimate is ₹722...
分析記事 • Nov 11Market Cool On Solara Active Pharma Sciences Limited's (NSE:SOLARA) RevenuesIt's not a stretch to say that Solara Active Pharma Sciences Limited's ( NSE:SOLARA ) price-to-sales (or "P/S") ratio...
Buy Or Sell Opportunity • Nov 06Now 22% undervalued after recent price dropOver the last 90 days, the stock has fallen 4.3% to ₹563. The fair value is estimated to be ₹722, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has declined by 3.9% over the last 3 years. Meanwhile, the company has become profitable. Revenue is forecast to grow by 44% in a year. Earnings are forecast to grow by 2,318% in the next year.
お知らせ • Oct 29Solara Active Pharma Sciences Limited to Report Q2, 2026 Results on Nov 05, 2025Solara Active Pharma Sciences Limited announced that they will report Q2, 2026 results on Nov 05, 2025
お知らせ • Sep 02Solara Active Pharma Sciences Limited, Annual General Meeting, Sep 25, 2025Solara Active Pharma Sciences Limited, Annual General Meeting, Sep 25, 2025, at 10:30 Indian Standard Time.
Reported Earnings • Jul 26First quarter 2026 earnings released: EPS: ₹2.46 (vs ₹3.50 loss in 1Q 2025)First quarter 2026 results: EPS: ₹2.46 (up from ₹3.50 loss in 1Q 2025). Revenue: ₹3.19b (down 12% from 1Q 2025). Net income: ₹105.2m (up ₹239.8m from 1Q 2025). Profit margin: 3.3% (up from net loss in 1Q 2025). The move to profitability was driven by lower expenses. Revenue is forecast to grow 19% p.a. on average during the next 2 years, compared to a 10% growth forecast for the Pharmaceuticals industry in India. Over the last 3 years on average, earnings per share has fallen by 26% per year but the company’s share price has increased by 22% per year, which means it is well ahead of earnings.
分析記事 • Jul 19Further Upside For Solara Active Pharma Sciences Limited (NSE:SOLARA) Shares Could Introduce Price Risks After 29% BounceSolara Active Pharma Sciences Limited ( NSE:SOLARA ) shareholders have had their patience rewarded with a 29% share...
お知らせ • Jul 18Solara Active Pharma Sciences Limited to Report Q1, 2026 Results on Jul 25, 2025Solara Active Pharma Sciences Limited announced that they will report Q1, 2026 results on Jul 25, 2025
分析記事 • Jun 26These 4 Measures Indicate That Solara Active Pharma Sciences (NSE:SOLARA) Is Using Debt Reasonably WellThe external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...
New Risk • Jun 25New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Indian stocks, typically moving 7.7% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Interest payments are not well covered by earnings (0.9x net interest cover). Minor Risk Share price has been volatile over the past 3 months (7.7% average weekly change).
Board Change • May 21High number of new directorsThere are 5 new directors who have joined the board in the last 3 years. CEO & MD Sandeep Rao was the last director to join the board, commencing their role in 2025. The company’s lack of board continuity is considered a risk according to the Simply Wall St Risk Model.
お知らせ • May 10Solara Active Pharma Sciences Limited to Report Q4, 2025 Results on May 15, 2025Solara Active Pharma Sciences Limited announced that they will report Q4, 2025 results on May 15, 2025
お知らせ • Feb 23Solara Active Pharma Sciences Limited Announces Resignation of Poorvank Purohit as CEOSolara Active Pharma Sciences Limited at the Board of Directors meeting held on February 21, 2025 Mr. Poorvank Purohit tendered his resignation as the CEO of the Company, with effect from February 21, 2025, citing personal reasons.
お知らせ • Feb 21+ 2 more updatesSolara Active Pharma Sciences Limited Approves Closure of Solara Active Pharma Sciences LTDA, BrazilSolara Active Pharma Sciences Limited at its board meeting held on February 21, 2025, transacted and approved the proposal for closure of Solara Active Pharma Sciences LTDA, Brazil, Wholly Owned Subsidiary of the Company as there were no operations.
分析記事 • Jan 29Market Cool On Solara Active Pharma Sciences Limited's (NSE:SOLARA) Revenues Pushing Shares 25% LowerUnfortunately for some shareholders, the Solara Active Pharma Sciences Limited ( NSE:SOLARA ) share price has dived 25...
Reported Earnings • Jan 25Third quarter 2025 earnings released: EPS: ₹2.03 (vs ₹76.34 loss in 3Q 2024)Third quarter 2025 results: EPS: ₹2.03 (up from ₹76.34 loss in 3Q 2024). Revenue: ₹3.02b (up 21% from 3Q 2024). Net income: ₹80.9m (up ₹2.83b from 3Q 2024). Profit margin: 2.7% (up from net loss in 3Q 2024). Revenue is forecast to grow 12% p.a. on average during the next 3 years, compared to a 11% growth forecast for the Pharmaceuticals industry in India. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 66 percentage points per year, which is a significant difference in performance.
お知らせ • Jan 25Solara Active Pharma Sciences Limited Revises Earnings Guidance for the Year 2025Solara Active Pharma Sciences Limited revised earnings guidance for the year 2025. The company will not get to the INR 14,000 million - INR 15,000 million range. The company will be more in the INR 13,000 million - INR 14,000 million range, which means that there is a drop in approximately INR 1,000 million of revenue.
お知らせ • Jan 16Solara Active Pharma Sciences Limited to Report Q3, 2025 Results on Jan 24, 2025Solara Active Pharma Sciences Limited announced that they will report Q3, 2025 results on Jan 24, 2025
New Risk • Jan 16New major risk - Shareholder dilutionThe company's shareholders have been substantially diluted in the past year. Increase in shares outstanding: 33% This is considered a major risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. This is currently the only risk that has been identified for the company.
Reported Earnings • Oct 24Second quarter 2025 earnings released: EPS: ₹2.54 (vs ₹4.77 loss in 2Q 2024)Second quarter 2025 results: EPS: ₹2.54 (up from ₹4.77 loss in 2Q 2024). Revenue: ₹3.47b (down 18% from 2Q 2024). Net income: ₹80.1m (up ₹251.7m from 2Q 2024). Profit margin: 2.3% (up from net loss in 2Q 2024). Revenue is forecast to grow 13% p.a. on average during the next 3 years, compared to a 11% growth forecast for the Pharmaceuticals industry in India. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 86 percentage points per year, which is a significant difference in performance.
お知らせ • Oct 14Solara Active Pharma Sciences Limited to Report Q2, 2025 Results on Oct 21, 2024Solara Active Pharma Sciences Limited announced that they will report Q2, 2025 results on Oct 21, 2024
Recent Insider Transactions • Sep 29Independent Chairman recently bought ₹2.4m worth of stockOn the 26th of September, Ramakrishnan Rajagopal bought around 3k shares on-market at roughly ₹808 per share. This transaction increased Ramakrishnan's direct individual holding by 2x at the time of the trade. This was the largest purchase by an insider in the last 3 months. This was Ramakrishnan's only on-market trade for the last 12 months.
分析記事 • Sep 13The Market Lifts Solara Active Pharma Sciences Limited (NSE:SOLARA) Shares 26% But It Can Do MoreSolara Active Pharma Sciences Limited ( NSE:SOLARA ) shares have continued their recent momentum with a 26% gain in the...
お知らせ • Aug 28Solara Active Pharma Sciences Limited, Annual General Meeting, Sep 20, 2024Solara Active Pharma Sciences Limited, Annual General Meeting, Sep 20, 2024, at 10:00 Indian Standard Time.
Price Target Changed • Jul 23Price target increased by 40% to ₹485Up from ₹347, the current price target is provided by 1 analyst. New target price is 20% below last closing price of ₹604. Stock is up 54% over the past year. The company is forecast to post earnings per share of ₹8.30 next year compared to a net loss per share of ₹158 last year.
Reported Earnings • Jul 23First quarter 2025 earnings released: ₹3.50 loss per share (vs ₹5.43 loss in 1Q 2024)First quarter 2025 results: ₹3.50 loss per share (improved from ₹5.43 loss in 1Q 2024). Revenue: ₹3.63b (up 3.2% from 1Q 2024). Net loss: ₹134.6m (loss narrowed 31% from 1Q 2024). Revenue is forecast to grow 13% p.a. on average during the next 3 years, compared to a 9.9% growth forecast for the Pharmaceuticals industry in India. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 86 percentage points per year, which is a significant difference in performance.
分析記事 • Jul 20Further Upside For Solara Active Pharma Sciences Limited (NSE:SOLARA) Shares Could Introduce Price Risks After 30% BounceSolara Active Pharma Sciences Limited ( NSE:SOLARA ) shareholders are no doubt pleased to see that the share price has...
お知らせ • Jul 16Solara Active Pharma Sciences Limited to Report Q1, 2025 Results on Jul 22, 2024Solara Active Pharma Sciences Limited announced that they will report Q1, 2025 results on Jul 22, 2024
Price Target Changed • Jun 20Price target increased by 9.7% to ₹381Up from ₹347, the current price target is an average from 2 analysts. New target price is 15% below last closing price of ₹448. Stock is up 22% over the past year. The company is forecast to post earnings per share of ₹8.70 next year compared to a net loss per share of ₹158 last year.
Buy Or Sell Opportunity • Jun 06Now 25% overvaluedOver the last 90 days, the stock has fallen 1.0% to ₹425. The fair value is estimated to be ₹339, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has declined by 3.4% over the last 3 years. Meanwhile, the company became loss making. Revenue is forecast to grow by 12% in a year. Earnings are forecast to grow by 84% in the next year.
分析記事 • Jun 05Slammed 32% Solara Active Pharma Sciences Limited (NSE:SOLARA) Screens Well Here But There Might Be A CatchSolara Active Pharma Sciences Limited ( NSE:SOLARA ) shareholders won't be pleased to see that the share price has had...
New Risk • May 24New minor risk - Shareholder dilutionThe company's shareholders have been diluted in the past year. Increase in shares outstanding: 33% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Debt is not well covered by operating cash flow (15% operating cash flow to total debt). Share price has been highly volatile over the past 3 months (10.0% average weekly change). Minor Risk Shareholders have been diluted in the past year (33% increase in shares outstanding).
お知らせ • May 23Solara Active Pharma Sciences Limited to Report Q4, 2024 Results on May 29, 2024Solara Active Pharma Sciences Limited announced that they will report Q4, 2024 results on May 29, 2024
分析記事 • May 11A Look At The Fair Value Of Solara Active Pharma Sciences Limited (NSE:SOLARA)Key Insights Solara Active Pharma Sciences' estimated fair value is ₹457 based on 2 Stage Free Cash Flow to Equity...
Buy Or Sell Opportunity • May 03Now 21% overvalued after recent price riseOver the last 90 days, the stock has risen 38% to ₹554. The fair value is estimated to be ₹458, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has declined by 3.4% over the last 3 years. Meanwhile, the company became loss making. Revenue is forecast to grow by 16% in a year. Earnings are forecast to grow by 81% in the next year.
Buy Or Sell Opportunity • Apr 19Now 20% overvalued after recent price riseOver the last 90 days, the stock has risen 35% to ₹552. The fair value is estimated to be ₹458, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has declined by 3.4% over the last 3 years. Meanwhile, the company became loss making. Revenue is forecast to grow by 16% in a year. Earnings are forecast to grow by 81% in the next year.
分析記事 • Apr 19Investors Still Aren't Entirely Convinced By Solara Active Pharma Sciences Limited's (NSE:SOLARA) Revenues Despite 28% Price JumpSolara Active Pharma Sciences Limited ( NSE:SOLARA ) shareholders would be excited to see that the share price has had...
Price Target Changed • Apr 04Price target decreased by 15% to ₹350Down from ₹410, the current price target is an average from 2 analysts. New target price is 15% below last closing price of ₹412. Stock is up 22% over the past year. The company posted a net loss per share of ₹6.16 last year.
お知らせ • Mar 25An undisclosed buyer agreed to acquire SeQuent Penems Private Limited from Solara Active Pharma Sciences Limited (NSEI:SOLARA).An undisclosed buyer agreed to acquire SeQuent Penems Private Limited from Solara Active Pharma Sciences Limited (NSEI:SOLARA) on March 25, 2024.
分析記事 • Mar 13Is Solara Active Pharma Sciences (NSE:SOLARA) A Risky Investment?Warren Buffett famously said, 'Volatility is far from synonymous with risk.' It's only natural to consider a company's...
分析記事 • Feb 23Even With A 26% Surge, Cautious Investors Are Not Rewarding Solara Active Pharma Sciences Limited's (NSE:SOLARA) Performance CompletelyDespite an already strong run, Solara Active Pharma Sciences Limited ( NSE:SOLARA ) shares have been powering on, with...
Reported Earnings • Feb 16Third quarter 2024 earnings released: ₹76.49 loss per share (vs ₹0.12 profit in 3Q 2023)Third quarter 2024 results: ₹76.49 loss per share (down from ₹0.12 profit in 3Q 2023). Revenue: ₹2.49b (down 37% from 3Q 2023). Net loss: ₹2.75b (down ₹2.76b from profit in 3Q 2023). Revenue is forecast to grow 11% p.a. on average during the next 3 years, compared to a 11% growth forecast for the Pharmaceuticals industry in India. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 76 percentage points per year, which is a significant difference in performance.
お知らせ • Feb 14Solara Active Pharma Sciences Limited Announces the Resignation of P.V. Raghavendra Rao as Chief Financial OfficerSolara Active Pharma Sciences Limited at its meeting held on February 14, 2024 announced that Mr. P.V. Raghavendra Rao resigned as Chief Financial Officer of the Company from the close of business hours on February 15, 2024, due to personal reasons.
お知らせ • Feb 06Solara Active Pharma Sciences Limited to Report Q3, 2024 Results on Feb 14, 2024Solara Active Pharma Sciences Limited announced that they will report Q3, 2024 results on Feb 14, 2024
分析記事 • Jan 04Further Upside For Solara Active Pharma Sciences Limited (NSE:SOLARA) Shares Could Introduce Price Risks After 25% BounceSolara Active Pharma Sciences Limited ( NSE:SOLARA ) shareholders would be excited to see that the share price has had...
Board Change • Dec 01High number of new directorsThere are 5 new directors who have joined the board in the last 3 years. Independent Director Rajendra Srivastava was the last director to join the board, commencing their role in 2023. The company’s lack of board continuity is considered a risk according to the Simply Wall St Risk Model.
Reported Earnings • Nov 16Second quarter 2024 earnings released: ₹4.77 loss per share (vs ₹2.77 loss in 2Q 2023)Second quarter 2024 results: ₹4.77 loss per share (further deteriorated from ₹2.77 loss in 2Q 2023). Revenue: ₹4.26b (up 26% from 2Q 2023). Net loss: ₹171.6m (loss widened 72% from 2Q 2023). Revenue is forecast to grow 13% p.a. on average during the next 2 years, compared to a 10% growth forecast for the Pharmaceuticals industry in India. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 67 percentage points per year, which is a significant difference in performance.
お知らせ • Oct 20Solara Active Pharma Sciences Limited Appoints P V Raghavendra Rao as Chief Financial OfficerSolara Active Pharma Sciences Limited at its board meeting held on October 19, 2023, approved the appointment of Mr. P V Raghavendra Rao as Chief Financial Officer (CFO) of the Company and designated him as Key Managerial Personnel with effect from October 26, 2023. Mr. P V Raghavendra Rao is a Chartered Accountant from the Institute of Chartered Accountants of India and has close to 23 years of post-qualification work experience. Mr. Rao has a strong track record of handling multiple industries including pharmaceuticals. He comes from Sequent Scientific Limited, where he was the Chief Financial Officer. Before this, he was at Macleods Pharmaceuticals Ltd. and Dr. Reddy's Laboratories Limited, for over 14 years where he handled various roles in finance such as Finance Head Pharmaceutical Services and Active Ingredients, Finance Head FTOs (Formulation Technical Operations), Finance Head Rest of World Markets and Finance Head Integrated Product Development Organization. Prior to Dr. Reddy's he was at New Holland Tractors. Mr. Rao started his career at Indo Asian Fusegear Limited, India, where he worked for 2 years.
Price Target Changed • Oct 11Price target decreased by 9.0% to ₹407Down from ₹447, the current price target is an average from 3 analysts. New target price is 20% above last closing price of ₹338. Stock is down 19% over the past year. The company is forecast to post earnings per share of ₹18.00 next year compared to a net loss per share of ₹6.16 last year.
Recent Insider Transactions • Sep 04Independent Director recently sold ₹183k worth of stockOn the 28th of August, Ramakrishnan Rajagopal sold around 500 shares on-market at roughly ₹366 per share. This transaction amounted to 100% of their direct individual holding at the time of the trade. In the last 3 months, they made an even bigger sale worth ₹7.3m. Insiders have been net sellers, collectively disposing of ₹25m more than they bought in the last 12 months.
お知らせ • Aug 22Solara Active Pharma Sciences Limited, Annual General Meeting, Sep 15, 2023Solara Active Pharma Sciences Limited, Annual General Meeting, Sep 15, 2023, at 09:30 Indian Standard Time. Agenda: To consider the Audited Standalone Financial Statements of the Company for the Financial Year ended March 31, 2023, together with the Reports of Board of Directors and Auditors thereon; to consider the Audited Consolidated Financial Statements of the Company for the Financial Year ended March 31, 2023, and the Report of Auditors thereon; to consider Board changes; and to consider any other matter thereof.
Buying Opportunity • Aug 17Now 20% undervalued after recent price dropOver the last 90 days, the stock is down 1.0%. The fair value is estimated to be ₹457, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has declined by 3.1% over the last 3 years. Meanwhile, the company became loss making.
Reported Earnings • Aug 16First quarter 2024 earnings released: ₹5.43 loss per share (vs ₹4.56 loss in 1Q 2023)First quarter 2024 results: ₹5.43 loss per share (further deteriorated from ₹4.56 loss in 1Q 2023). Revenue: ₹3.52b (up 6.7% from 1Q 2023). Net loss: ₹195.5m (loss widened 19% from 1Q 2023). Revenue is forecast to grow 13% p.a. on average during the next 2 years, compared to a 9.9% growth forecast for the Pharmaceuticals industry in India. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 67 percentage points per year, which is a significant difference in performance.
お知らせ • Aug 05+ 1 more updateSolara Active Pharma Sciences Limited Announces Resignation of DirectorsSolara Active Pharma Sciences Limited informed that following directors have resigned from the directorship of the company with effect from August 5, 2023, Mr. Aditya Puri (DIN: 00062650) has resigned from the position of Chairman and Non- Executive Director of the Company due to personal reasons. Mrs. Vineeta Rai (DIN: 07013113) has resigned from the position of Non- Executive- Independent Director of the Company due to personal reasons.Names of listed entities in which Mrs. Vineeta Rai (DIN: 07013113) holds directorships, indicating the category of directorship and membership of board committees:- Indraprastha Medical Corporation Limited as Independent Director. Membership of Board Committees: Audit Committee Member and Nomination and remuneration Committee Member.
Board Change • Aug 04High number of new directorsThere are 5 new directors who have joined the board in the last 3 years. MD, CEO & Director Poorvank Purohit was the last director to join the board, commencing their role in 2023. The company’s lack of board continuity is considered a risk according to the Simply Wall St Risk Model.
お知らせ • Aug 03Solara Active Pharma Sciences Limited Announces Executive ChangesSolara Active Pharma Sciences Limited announced that Mr. Rajeev Singh has tendered his resignation from the position of Chief Human Resource Officer (CHRO) for better future prospects, the resignation letter is enclosed herewith as Annexure A. As a result, he will cease to be Head of Human Resources (CHRO) with effect from the close of business hours on August 31, 2023. Mr. Pagadala Srinivasan has been appointed as Chief Human Resource Officer(CHRO) with effect from August 1, 2023. He has over 23 years' experience working across reputed pharma companies in India. He joins from Biological E. Ltd. His experience is in handling all gamut of HR.
お知らせ • Aug 01+ 1 more updateSolara Active Pharma Sciences Limited Announces Resignation of S Hariharan as Executive DirectorSolara Active Pharma Sciences Limited announced that Mr. S Hariharan (DIN: 05297969) has resigned from the position of Executive Director of the Company from the close of business hours on July 31, 2023, due to personal reasons. The Company will announce his successor in due course. Date of cessation:The resignation is effective from the close of business hours on July 31, 2023.
お知らせ • Jul 06Solara Active Pharma Sciences Limited Announces Resignation of Jitesh Devendra as A Managing Director and DirectorSolara Active Pharma Sciences Limited announced the resignation of Mr. Jitesh Devendra (DIN: 06469234) as a Managing Director (MD) and Director and KMP of the company due to pre-occupation. In view of resignation of Mr. Jitesh Devendra (DIN: 06469234) as Managing Director w.e.f. July 5, 2023, the Board of Directors of the Company have also approved the reconstitution of Risk Management Committee and Corporate Social Responsibility Committee.
Recent Insider Transactions • Jun 29MD & Director recently sold ₹5.5m worth of stockOn the 23rd of June, Jitesh Devendra sold around 15k shares on-market at roughly ₹369 per share. This transaction amounted to 4.8% of their direct individual holding at the time of the trade. In the last 3 months, there was an even bigger sale from another insider worth ₹7.3m. Insiders have been net sellers, collectively disposing of ₹22m more than they bought in the last 12 months.
Recent Insider Transactions • Jun 13Independent Director recently sold ₹7.3m worth of stockOn the 7th of June, Ramakrishnan Rajagopal sold around 21k shares on-market at roughly ₹354 per share. This transaction amounted to 98% of their direct individual holding at the time of the trade. This was the largest sale by an insider in the last 3 months. Insiders have been net sellers, collectively disposing of ₹11m more than they bought in the last 12 months.
Recent Insider Transactions • May 31Insider recently sold ₹3.6m worth of stockOn the 26th of May, Chaitanya Devendra sold around 10k shares on-market at roughly ₹359 per share. This transaction amounted to 19% of their direct individual holding at the time of the trade. This was the largest sale by an insider in the last 3 months. Insiders have been net sellers, collectively disposing of ₹3.3m more than they bought in the last 12 months.
Recent Insider Transactions • May 21Insider recently sold ₹1.8m worth of stockOn the 17th of May, Sajjan Devendra sold around 5k shares on-market at roughly ₹369 per share. This transaction amounted to 33% of their direct individual holding at the time of the trade. This was the largest sale by an insider in the last 3 months. Despite this recent sale, insiders have collectively bought ₹306k more than they sold in the last 12 months.
Price Target Changed • May 17Price target decreased by 8.9% to ₹447Down from ₹491, the current price target is an average from 4 analysts. New target price is 18% above last closing price of ₹378. Stock is down 16% over the past year. The company is forecast to post earnings per share of ₹16.97 next year compared to a net loss per share of ₹6.16 last year.
Reported Earnings • May 13Full year 2023 earnings: EPS exceeds analyst expectations while revenues lag behindFull year 2023 results: ₹6.16 loss per share (improved from ₹16.18 loss in FY 2022). Revenue: ₹14.7b (up 16% from FY 2022). Net loss: ₹221.7m (loss narrowed 62% from FY 2022). Revenue missed analyst estimates by 1.7%. Earnings per share (EPS) exceeded analyst estimates by 33%. Revenue is forecast to grow 13% p.a. on average during the next 2 years, compared to a 11% growth forecast for the Pharmaceuticals industry in India. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 80 percentage points per year, which is a significant difference in performance.
分析記事 • May 12Solara Active Pharma Sciences Limited's (NSE:SOLARA) Intrinsic Value Is Potentially 81% Above Its Share PriceKey Insights Using the 2 Stage Free Cash Flow to Equity, Solara Active Pharma Sciences fair value estimate is ₹747...
お知らせ • May 05Solara Active Pharma Sciences Limited to Report Q4, 2023 Results on May 12, 2023Solara Active Pharma Sciences Limited announced that they will report Q4, 2023 results on May 12, 2023
Price Target Changed • Apr 08Price target decreased by 8.1% to ₹491Down from ₹534, the current price target is an average from 3 analysts. New target price is 45% above last closing price of ₹339. Stock is down 57% over the past year. The company is forecast to post a net loss per share of ₹10.80 next year compared to a net loss per share of ₹16.18 last year.
お知らせ • Jan 31USFDA concludes inspection at Solara's Visakhapatnam (Vizag) facility with Zero 483 inspectional observationsSolara Active Pharma Sciences Ltd. (Solara) announced that its new state-of-the-art multipurpose API manufacturing facility at Visakhapatnam (Vizag), Andhra Pradesh completed successfully the inspection carried out by the US Food and Drug Administration (US FDA or Agency). The Agency, with its designated investigator, inspected the facility from 23rd to 26th January 2023. The inspection established that the site is in an "Acceptable State of Compliance" with Zero Form 483 inspectional observations from the agency. The Vizag facility of the Company is a green field project spread over 40 acres and has dedicated facilities for manufacturing Ibuprofen API and multipurpose facility in phase 1. The facility has also started validating other APIs to register in various regulated markets across the globe. The site offers a unique capability to the Company for manufacturing various APIs with scale and operational flexibility to achieve a competitive advantage. The site positions Solara as the only Global Company offering Ibuprofen from two USFDA-approved manufacturing sites (Puducherry and Vizag), enhancing supplies for its global partners. Earlier, in November 2022, Solara's Vizag facility had received a Certificate of Suitability (CEP) approval for the manufacture of Ibuprofen API from the European Directorate for the Quality of Medicines (EDQM), the first international regulatory approval for this new facility.
Reported Earnings • Jan 26Third quarter 2023 earnings released: EPS: ₹0.12 (vs ₹38.93 loss in 3Q 2022)Third quarter 2023 results: EPS: ₹0.12 (up from ₹38.93 loss in 3Q 2022). Revenue: ₹4.02b (up 301% from 3Q 2022). Net income: ₹4.50m (up ₹1.40b from 3Q 2022). Profit margin: 0.1% (up from net loss in 3Q 2022). The move to profitability was driven by higher revenue. Revenue is forecast to grow 12% p.a. on average during the next 3 years, compared to a 11% growth forecast for the Pharmaceuticals industry in India. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 76 percentage points per year, which is a significant difference in performance.
お知らせ • Jan 26Solara Active Pharma Sciences Limited Appoints Poorvank Purohit as Chief Executive Officer, Effective from 3 February, 2023Solara Active Pharma Sciences Limited informed that the Board of Directors of the Company has taken on record/approved the following changes in the Key Managerial Personnel (KMP) at its meeting held on January 25, 2023. The board approved the appointment of Mr. Poorvank Purohit as the Chief Executive Officer. The position of CEO has been vacant since the exit of previous MD & CEO, Mr. Rajender Rao Juvvadi. This appointment is effective from 3rd February, 2023 Mr. Purohit hold a Bachelor in Chemical Engineering from M.S.Ramaiah Institute of Technology, Bangalore. He has also done Executive MBA from IIM Bangalore and completed Advance Management Program from Wharton School. He started his career as Management Trainee with Ranbaxy and progressed through various roles in leading pharma companies Hikel, Alembic, Jubliant Organosys - strong B2B experience in both APIs and Finished Dosage Forms. He is currently the Chief Operating Officer (COO) with R L Fine Chem Pvt Ltd, Bangalore. He has to his credit experience of turning round companies for exponential growth and sustainable organization. His achievement includes building B2B businesses across geographies by establishing strong network and relationship with top Innovator/Generic/Dossier companies including CDMO companies. Holds a strong technical, commercial and management background.
お知らせ • Jan 20Solara Active Pharma Sciences Limited to Report Q3, 2023 Results on Jan 25, 2023Solara Active Pharma Sciences Limited announced that they will report Q3, 2023 results at 12:08 PM, Indian Standard Time on Jan 25, 2023
Board Change • Nov 16High number of new directorsThere are 6 new directors who have joined the board in the last 3 years. Managing Director Jitesh Devendra was the last director to join the board, commencing their role in 2022. The company’s lack of board continuity is considered a risk according to the Simply Wall St Risk Model.
Reported Earnings • Nov 11Second quarter 2023 earnings released: ₹2.77 loss per share (vs ₹8.27 profit in 2Q 2022)Second quarter 2023 results: ₹2.77 loss per share (down from ₹8.27 profit in 2Q 2022). Revenue: ₹3.38b (down 16% from 2Q 2022). Net loss: ₹99.6m (down 134% from profit in 2Q 2022). Revenue is forecast to grow 15% p.a. on average during the next 3 years, compared to a 11% growth forecast for the Pharmaceuticals industry in India. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 65 percentage points per year, which is a significant difference in performance.
分析記事 • Nov 08Estimating The Intrinsic Value Of Solara Active Pharma Sciences Limited (NSE:SOLARA)Today we'll do a simple run through of a valuation method used to estimate the attractiveness of Solara Active Pharma...
Buying Opportunity • Oct 31Now 21% undervaluedOver the last 90 days, the stock is up 1.3%. The fair value is estimated to be ₹501, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has been flat over the last 3 years. Meanwhile, the company became loss making. Revenue is forecast to grow by 26% in a year. Earnings is forecast to grow by 98% in the next year.
Buying Opportunity • Oct 07Now 20% undervaluedOver the last 90 days, the stock is up 14%. The fair value is estimated to be ₹547, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has been flat over the last 3 years. Meanwhile, the company became loss making. Revenue is forecast to grow by 26% in a year. Earnings is forecast to grow by 98% in the next year.
分析記事 • Sep 30Is Solara Active Pharma Sciences (NSE:SOLARA) A Risky Investment?David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...
Buying Opportunity • Sep 16Now 20% undervaluedOver the last 90 days, the stock is up 22%. The fair value is estimated to be ₹537, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has been flat over the last 3 years. Meanwhile, the company became loss making. Revenue is forecast to grow by 26% in a year. Earnings is forecast to grow by 98% in the next year.
Recent Insider Transactions • Sep 03Insider recently bought ₹390k worth of stockOn the 29th of August, Shankarlal Devendra bought around 900 shares on-market at roughly ₹433 per share. This transaction increased Shankarlal Devendra's direct individual holding by 9x at the time of the trade. In the last 3 months, there was an even bigger purchase from another insider worth ₹1.3m. Insiders have collectively bought ₹117m more in shares than they have sold in the last 12 months.
Recent Insider Transactions • Aug 26Insider recently bought ₹1.3m worth of stockOn the 19th of August, Pooja Srisrimal bought around 3k shares on-market at roughly ₹435 per share. This was the largest purchase by an insider in the last 3 months. Insiders have collectively bought ₹124m more in shares than they have sold in the last 12 months.
Buying Opportunity • Aug 19Now 20% undervaluedThe stock has been flat over the last 90 days. The fair value is estimated to be ₹544, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has been flat over the last 3 years. Meanwhile, the company became loss making. Revenue is forecast to grow by 26% in a year. Earnings is forecast to grow by 98% in the next year.
Reported Earnings • Aug 03Full year 2022 earnings: EPS and revenues miss analyst expectationsFull year 2022 results: ₹16.18 loss per share (down from ₹69.00 profit in FY 2021). Revenue: ₹12.7b (down 22% from FY 2021). Net loss: ₹581.5m (down 126% from profit in FY 2021). Revenue missed analyst estimates by 15%. Earnings per share (EPS) were also behind analyst expectations. Over the next year, revenue is forecast to grow 25%, compared to a 13% growth forecast for the pharmaceuticals industry in India. Over the last 3 years on average, earnings per share has fallen by 49% per year but the company’s share price has increased by 1% per year, which means it is well ahead of earnings.
分析記事 • Aug 03Are Investors Undervaluing Solara Active Pharma Sciences Limited (NSE:SOLARA) By 22%?Does the August share price for Solara Active Pharma Sciences Limited ( NSE:SOLARA ) reflect what it's really worth...
分析記事 • Jun 19Solara Active Pharma Sciences (NSE:SOLARA) Is Making Moderate Use Of DebtThe external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...